Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic dendritic cell cancer vaccine
- Development stage
- Preclinical
- Lead developer
- Lunai Bioworks
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intradermal, Intramuscular
01
Overview
The allogeneic dendritic cell cancer vaccine (DCCV) is an engineered cell therapy platform developed by Renovaro Biosciences for the treatment of various solid tumors. This platform utilizes dendritic cells derived from CD34+ hematopoietic stem cells (HSCs) that are genetically modified using a tri-cistronic lentiviral vector to overexpress CD93, CD40L (CD154), and CXCL13. The engineered dendritic cells are "educated" through co-culture with whole tumor lysates, allowing them to present a broad spectrum of tumor-associated antigens. The vaccine's mechanism of action involves the stimulation of both innate and adaptive immune responses, leading to the proliferation and tumor infiltration of CD4+ T cells, CD8+ T cells, and NK cells. Preclinical studies in humanized mouse models have demonstrated significant tumor regression in pancreatic cancer, and the platform is being explored for other indications including triple-negative breast cancer and hepatocellular carcinoma.
- Other names
- DCCVCD34-derived allogeneic dendritic cell cancer vaccineCD-34-derived allogeneic dendritic cell cancer vaccineCD 34-derived allogeneic dendritic cell cancer vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CD40 (Cluster of differentiation 40 receptor)CD93L (CD93 ligands)CXCR5 (C-X-C motif chemokine receptor 5)γδ TCR (T-cell receptor)
Beyond the preview
Go deeper on allogeneic dendritic cell cancer vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic dendritic cell cancer vaccine.